Table 3.
Base case results (95% Credible Intervals) for cohort of 3200 women. All costs are in 2019 United States Dollars (US$)
| Strategy | Cost | Incremental cost | Infections | Infections averted | ICER |
|---|---|---|---|---|---|
| Vaccine only | $ 19,639 (11,202–30,258) | base | 22 (17–27) | base | base |
| TDF after HBeAg test | $ 30,254 (21172–41,413) | $ 10,615 (7539–13,952) | 11 (9–14) | 11 (7–14) | $ 980 (689–1454) |
| TDF after PCR | $ 31,715 (22264–43,001) | dominated | 11 (9–16) | dominated | dominated |
| HBIG & TDF after PCR | $ 34,791 (24915–46,417) | dominated | 11 (9–15) | dominated | dominated |
| TDF after RDT | $ 39,845 (28439–52,958) | $ 9591 (4533–16,108) | 7 (5–10) | 4 (3–5) | $ 2489 (1267–4410) |
| HBIG after RDT | $ 42,275 (29,145–58,319) | dominated | 17 (12–22) | dominated | dominated |
DNA Deoxyribonucleic acid, HBeAg hepatitis B envelope antigen, HBV hepatitis B virus, ICER incremental cost-effectiveness ratio, RDT Rapid diagnostic test, TDF Tenofovir Disoproxil Fumarate